176 related articles for article (PubMed ID: 8896434)
41. Phase II study of tacrolimus and methotrexate for prophylaxis of acute graft-versus-host disease after HLA-A, B, and DRB1 genotypically mismatched unrelated bone marrow transplantation among Japanese patients.
Nishida T; Murayama T; Hirai H; Okamoto S; Sao H; Hara M; Kanamori H; Atsuta Y; Matsuo K; Morishima Y; Kodera Y
Int J Hematol; 2009 Jan; 89(1):98-105. PubMed ID: 19052693
[TBL] [Abstract][Full Text] [Related]
42. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation.
Atkinson K; Downs K
Bone Marrow Transplant; 1995 Dec; 16(6):755-8. PubMed ID: 8750265
[TBL] [Abstract][Full Text] [Related]
43. [CD25 monoclonal antibody for GVHD prophylaxis in non-T-cell depleted haploidentical bone marrow transplantation for treatment of childhood leukemia].
Chen HR; Ji SQ; Yan HM; Wang HX; Liu J; Xue M; Zhu L
Zhonghua Er Ke Za Zhi; 2004 Apr; 42(4):294-8. PubMed ID: 15157394
[TBL] [Abstract][Full Text] [Related]
44. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation.
Bolwell B; Sobecks R; Pohlman B; Andresen S; Rybicki L; Kuczkowski E; Kalaycio M
Bone Marrow Transplant; 2004 Oct; 34(7):621-5. PubMed ID: 15300236
[TBL] [Abstract][Full Text] [Related]
45. Combination of low-dose mycophenolate mofetil with cyclosporine and methotrexate as GVHD prophylaxis in unrelated donor allogeneic stem cell transplantation.
Zhu X; Lai X; Luo Y; Shi J; Tan Y; Zheng W; He J; Xie W; Li L; Zhang J; Ye X; Lin M; Cai Z; Huang H
Leuk Res; 2013 Sep; 37(9):1046-51. PubMed ID: 23849987
[TBL] [Abstract][Full Text] [Related]
46. [FK506 for the prophylaxis of graft-versus-host-disease after bone marrow transplantation from HLA-genotypically mismatched unrelated donor].
Nishida T; Haneda M; Kanie T; Murata M; Hamaguchi M; Minami S; Kodera Y
Rinsho Ketsueki; 1998 Aug; 39(8):574-9. PubMed ID: 9785975
[TBL] [Abstract][Full Text] [Related]
47. Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study.
Yeshurun M; Shpilberg O; Herscovici C; Shargian L; Dreyer J; Peck A; Israeli M; Levy-Assaraf M; Gruenewald T; Mechoulam R; Raanani P; Ram R
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1770-5. PubMed ID: 26033282
[TBL] [Abstract][Full Text] [Related]
48. Low-dose cyclosporin A with short-term methotrexate for graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation from human leukocyte antigen-identical siblings: a prospective phase II study in Japanese patients.
Kohno A; Morishita Y; Iida H; Sakamaki H; Yokozawa T; Kitaori K; Ozeki K; Matsuo K; Sao H
Int J Hematol; 2006 Jul; 84(1):83-9. PubMed ID: 16867909
[TBL] [Abstract][Full Text] [Related]
49. Prognostic impact of the dosage of methotrexate combined with tacrolimus for graft-versus-host disease prophylaxis after cord blood transplantation.
Adachi M; Yokota D; Hirata H; Koyauchi K; Dohtan S; Oka S; Sakamoto N; Takaba M; Takemura T; Nagata Y; Naito K; Ono T
Int J Hematol; 2021 Aug; 114(2):252-262. PubMed ID: 34086252
[TBL] [Abstract][Full Text] [Related]
50. Correlation between disparity for the minor histocompatibility antigen HA-1 and the development of acute graft-versus-host disease after allogeneic marrow transplantation.
Tseng LH; Lin MT; Hansen JA; Gooley T; Pei J; Smith AG; Martin EG; Petersdorf EW; Martin PJ
Blood; 1999 Oct; 94(8):2911-4. PubMed ID: 10515896
[TBL] [Abstract][Full Text] [Related]
51. Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes.
Uberti JP; Ayash L; Braun T; Reynolds C; Silver S; Ratanatharathorn V
Bone Marrow Transplant; 2004 Sep; 34(5):425-31. PubMed ID: 15273705
[TBL] [Abstract][Full Text] [Related]
52. Cyclosporin A and mini short-term methotrexate vs cyclosporin A as graft-versus-host disease prophylaxis in patients with beta thalassemia major undergoing allogeneic blood and marrow transplantation.
Iravani M; Mousavi A; Gholibeikian S; Bahar B; Samiee S; Ashouri A; Eghbal L; Ghavamzadeh A
Bone Marrow Transplant; 2005 Jun; 35(11):1095-9. PubMed ID: 15821773
[TBL] [Abstract][Full Text] [Related]
53. Unrelated cord blood transplant experience by the pediatric blood and marrow transplant consortium.
Yu LC; Wall DA; Sandler E; Chan KW; Grayson G; Kletzel M
Pediatr Hematol Oncol; 2001 Jun; 18(4):235-45. PubMed ID: 11400647
[TBL] [Abstract][Full Text] [Related]
54. Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1.
Przepiorka D; Saliba R; Cleary K; Fischer H; Tonai R; Fritsche H; Khouri IF; Folloder J; Ueno NT; Mehra R; Ippoliti C; Giralt S; Gajewski J; Donato M; Claxton D; Braunschweig I; van Besien K; Anderlini P; Andersson BS; Champlin R
Biol Blood Marrow Transplant; 2000; 6(2A):190-7. PubMed ID: 10816027
[TBL] [Abstract][Full Text] [Related]
55. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
56. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan.
Koga Y; Nagatoshi Y; Kawano Y; Okamura J
Bone Marrow Transplant; 2003 Jul; 32(2):171-6. PubMed ID: 12838282
[TBL] [Abstract][Full Text] [Related]
57. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate.
Nash RA; Pepe MS; Storb R; Longton G; Pettinger M; Anasetti C; Appelbaum FR; Bowden RA; Deeg HJ; Doney K
Blood; 1992 Oct; 80(7):1838-45. PubMed ID: 1391947
[TBL] [Abstract][Full Text] [Related]
58. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
Carnevale-Schianca F; Caravelli D; Gallo S; Coha V; D'Ambrosio L; Vassallo E; Fizzotti M; Nesi F; Gioeni L; Berger M; Polo A; Gammaitoni L; Becco P; Giraudo L; Mangioni M; Sangiolo D; Grignani G; Rota-Scalabrini D; Sottile A; Fagioli F; Aglietta M
Biol Blood Marrow Transplant; 2017 Mar; 23(3):459-466. PubMed ID: 28039079
[TBL] [Abstract][Full Text] [Related]
59. FK-506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated dog leukocyte antigen-nonidentical donors.
Storb R; Raff RF; Appelbaum FR; Deeg HJ; Fitzsimmons W; Graham TC; Pepe M; Pettinger M; Sale G; van der Jagt R
Transplantation; 1993 Oct; 56(4):800-7. PubMed ID: 7692635
[TBL] [Abstract][Full Text] [Related]
60. Prospective trial of mycophenolate mofetil-cyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and hematological malignancies.
Ostronoff F; Ostronoff M; Souto-Maior AP; Domingues M; Sucupira A; Manso DA; de Lima AK; Monteiro PG; Florêncio R; Calixto R
Clin Transplant; 2009; 23(1):33-8. PubMed ID: 18727660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
